Publications

Search Publications
Export 25 results:
[ Author(Desc)] Title Year
Filters: Keyword is Neoplasm Metastasis  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Aiello NM, Kang Y. Context-dependent EMT programs in cancer metastasis. J Exp Med. 2019 ;216(5):1016-1026.
Alesi GN, Jin L, Li D, Magliocca KR, Kang Y, Chen ZG, et al. RSK2 signals through stathmin to promote microtubule dynamics and tumor metastasis. Oncogene. 2016 ;35(41):5412-5421.
C
Celià-Terrassa T, Kang Y. Distinctive properties of metastasis-initiating cells. Genes Dev. 2016 ;30(8):892-908.
Celià-Terrassa T, Kang Y. Metastatic niche functions and therapeutic opportunities. Nat Cell Biol. 2018 ;20(8):868-877.
Celià-Terrassa T, Kang Y. Mouse genomic screen reveals novel host regulator of metastasis. Genome Biol. 2017 ;18(1):31.
Celià-Terrassa T, Liu DD, Choudhury A, Hang X, Wei Y, Zamalloa J, et al.. Normal and cancerous mammary stem cells evade interferon-induced constraint through the miR-199a-LCOR axis. Nat Cell Biol. 2017 ;19(6):711-723.
Celià-Terrassa T, Bastian C, Liu DD, Ell B, Aiello NM, Wei Y, et al.. Hysteresis control of epithelial-mesenchymal transition dynamics conveys a distinct program with enhanced metastatic ability. Nat Commun. 2018 ;9(1):5005.
E
Esposito M, Mondal N, Greco TM, Wei Y, Spadazzi C, Lin S-C, et al. Bone vascular niche E-selectin induces mesenchymal-epithelial transition and Wnt activation in cancer cells to promote bone metastasis. Nat Cell Biol. 2019 ;21(5):627-639.
F
Fan H, Wang X, Li W, Shen M, Wei Y, Zheng H, et al. ASB13 inhibits breast cancer metastasis through promoting SNAI2 degradation and relieving its transcriptional repression of YAP. Genes Dev. 2020 ;34(19-20):1359-1372.
Fang C, Kang Y. Cellular plasticity in bone metastasis. Bone. 2022 ;158:115693.
K
Kang Y. Imaging TGFβ Signaling in Mouse Models of Cancer Metastasis. Methods Mol Biol. 2016 ;1344:219-32.
L
Li W, Shen M, Jiang Y-Z, Zhang R, Zheng H, Wei Y, et al. Deubiquitinase USP20 promotes breast cancer metastasis by stabilizing SNAI2. Genes Dev. 2020 ;34(19-20):1310-1315.
Lu W, Kang Y. Epithelial-Mesenchymal Plasticity in Cancer Progression and Metastasis. Dev Cell. 2019 ;49(3):361-374.
Lu W, Kang Y. Cell lineage determinants as regulators of breast cancer metastasis. Cancer Metastasis Rev. 2016 ;35(4):631-644.
M
Monsivais D, Peng J, Kang Y, Matzuk MM. Activin-like kinase 5 (ALK5) inactivation in the mouse uterus results in metastatic endometrial carcinoma. Proc Natl Acad Sci U S A. 2019 ;116(9):3883-3892.
P
Peinado H, Zhang H, Matei IR, Costa-Silva B, Hoshino A, Rodrigues G, et al. Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer. 2017 ;17(5):302-317.
Q
Quinn JJ, Jones MG, Okimoto RA, Nanjo S, Chan MM, Yosef N, et al. Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts. Science. 2021 ;371(6532).
R
Ren G, Esposito M, Kang Y. Bone metastasis and the metastatic niche. J Mol Med (Berl). 2015 ;93(11):1203-12.
S
Shen M, Kang Y. Stresses in the metastatic cascade: molecular mechanisms and therapeutic opportunities. Genes Dev. 2020 ;34(23-24):1577-1598.
Shen M, Xie S, Rowicki M, Michel S, Wei Y, Hang X, et al. Therapeutic Targeting of Metadherin Suppresses Colorectal and Lung Cancer Progression and Metastasis. Cancer Res. 2021 ;81(4):1014-1025.
Spadazzi C, Mercatali L, Esposito M, Wei Y, Liverani C, De Vita A, et al. Trefoil factor-1 upregulation in estrogen-receptor positive breast cancer correlates with an increased risk of bone metastasis. Bone. 2021 ;144:115775.
Z
Zheng H, Li W, Kang Y. Tumor-Stroma Interactions in Bone Metastasis: Molecular Mechanisms and Therapeutic Implications. Cold Spring Harb Symp Quant Biol. 2016 ;81:151-161.
Zhuo W, Liu Y, Li S, Guo D, Sun Q, Jin J, et al. Long Noncoding RNA GMAN, Up-regulated in Gastric Cancer Tissues, Is Associated With Metastasis in Patients and Promotes Translation of Ephrin A1 by Competitively Binding GMAN-AS. Gastroenterology. 2019 ;156(3):676-691.e11.
Zijlstra A, Von Lersner A, Yu D, Borrello L, Oudin M, Kang Y, et al. The importance of developing therapies targeting the biological spectrum of metastatic disease. Clin Exp Metastasis. 2019 ;36(4):305-309.